Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Clinical Medicine Insights. Oncology|November 30, 2023
Circadian Clock Dysregulation and Prostate Cancer: A Molecular and Clinical OverviewDalia Kaakour, Bridget Fortin, Selma Masri, et al.
Clinical Medicine Insights. Oncology|October 3, 2022
Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial CarcinomaDavid J Benjamin, Nataliya Mar, Arash Rezazadeh Kalebasty
JCO Oncology Practice|December 10, 2020
Management of Advanced Prostate Cancer in Clinical Practice: Real-World Answers to Challenging DilemmasNataliya Mar, Arash Rezazadeh Kalebasty, Edward M Uchio
European Urology Oncology|January 24, 2025
Implications and Lessons from the Withdrawal of Sacituzumab Govitecan for Treating Advanced Urothelial CarcinomaDavid J Benjamin, Arash Rezazadeh Kalebasty, Nataliya Mar
European Urology Oncology|March 14, 2024
The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?David J Benjamin, Arash Rezazadeh Kalebasty, Vinay Prasad
Cancers|May 13, 2023
Prostate Cancer in Sexual Minorities: Epidemiology, Screening and Diagnosis, Treatment, and Quality of LifeOmid Yazdanpanah, David J Benjamin, Arash Rezazadeh Kalebasty
Integrative Cancer Therapies|March 29, 2025
The Role of Ayurveda in Prostate Cancer ManagementParnian Jabbari, Omid Yazdanpanah, David J Benjamin, et al.
Cancers|March 13, 2024
Supplement Use and Increased Risks of Cancer: Unveiling the Other Side of the CoinParnian Jabbari, Omid Yazdanpanah, David J Benjamin, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 4, 2023
Drug extravasation with Enfortumab vedotinChristopher Ryan Grant, Dimitri de Kouchkovsky, Arash Rezazadeh Kalebasty, et al.
Therapeutic Advances in Medical Oncology|March 1, 2024
A remnant never forgotten: the utility of circulating tumor DNA in treatment guidance of urachal cancerChristopher Ryan Grant, David J Benjamin, Scott Cramer, et al.
Pageof 8